SEBI Registration No: MF/036/97/7

DSP Healthcare Fund

Equity| Thematic | Pharma

DSP MUTUAL FUND

Fund Details

Fund Information

An open ended equity scheme investing in healthcare and pharmaceutical sector

Inception Date	Nov 30, 2018
Total AUM as of Jun 30, 2026	₹3,514.02 Crs
NAV as of Jul 14, 2026	Regular: ₹ 44.17 Direct: ₹ 49.40
Expense Ratio as of Jul 14, 2026	Regular: 2.01% Direct: 0.71%

Exit Load:

1% upto 1 Months

Benchmark

BSE HEALTHCARE (TRI)

Fund Managers

Names	Years of Experience	Managing Since
Chirag Dagli	24 Years	Managing this fund since December 2020

Portfolio As of Jun 30, 2026

Asset Allocation



Equity 93.2%

Debt 6.8%

Indian - Equity (76.1%)

Market Cap

Small Cap	56.2%	Mid Cap	15.8%
Large Cap	28%		

Sectors

PHARMACEUTICALS & BIOTECHNOLOGY	60.4%	INSURANCE	1.2%
HEALTHCARE SERVICES	14.3%	HEALTHCARE EQUIPMENT & SUPPLIES	0.2%

Holdings

Cipla Limited	8.4%	Cohance Lifesciences Limited	4.1%
IPCA Laboratories Limited	8.2%	Vijaya Diagnostic Centre Limited	3.6%
Sun Pharmaceutical Industries Limited	8.1%	Alembic Pharmaceuticals Limited	3.4%
Sai Life Sciences Limited	6.9%	Procter & Gamble Health Limited	2.9%
Gland Pharma Limited	6.5%	Rest	19.2%
Apollo Hospitals Enterprise Limited	4.8%		

International - Equity (17.2%)

Holdings

Illumina Inc	7.6%	Global X Funds - Global X Genomics & Biotechnology ETF	0.9%
Globus Medical Inc	5.7%	Abbott Laboratories	0.8%
Intuitive Surgical Inc	2%	Grail Inc	0.2%

Indian - Debt (6.8%)

Instrument Break-up

TREPS	100%

Credit Rating Profile

Cash & Equivalent	100%

Holdings

TREPS / Reverse Repo Investments	7.6%	Cash & cash equivalents	-0.9%

Indicators

Options	**Growth | IDCW**
Portfolio Turnover Ratio	**0.09** last 12 months
Ideal Holding Period	**10 Years+**

Performance (Regular Plan - Growth Option)

	1 Year		3 Years		5 Years		Since Inception	
	Fund	Benchmark	Fund	Benchmark	Fund	Benchmark	Fund	Benchmark
Lumpsum	10.74%	11.95%	21.74%	24.64%	14.63%	14.6%	21.51%	18.54%
SIP	27.53%	27.75%	15.84%	18.95%	18.27%	20.24%	20.62%	20.61%

Source : Internal, data as of Jul 14, 2026

It is not possible to invest directly in an index. Benchmark^ BSE HEALTHCARE (TRI). Date of allotment November 30, 2018. **Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments.** For performance in SEBI prescribed format, please visit https://www.dspim.com/invest/mutual-fund-schemes/equity-funds/Healthcare-fund/dspwh-regular-growth

Rolling Returns (Regular Plan - Growth Option) - Lumpsum

Time Period	Minimum	Median	Maximum	% times -ve returns	% times returns > 7%
6 Months	-18.9%	9.6%	77.6%	30%	55.9%
1 Year	-15.2%	21.1%	94.1%	22.3%	71.3%
3 Years	13.2%	21.3%	33%	0%	100%
5 Years	12.7%	24.1%	33.5%	0%	100%

Source : Internal, data as of Jul 14, 2026

The frequency of calculating rolling returns in the above table is 6M, 1Y, 3Y, 5Y and 10Y rolling returns on a daily basis since the inception of the fund. To illustrate, 1Y column shows average, minimum and maximum 1Y rolling returns (calculated on daily basis) an investor would have received if the investor had invested in the fund anytime since inception. % times negative returns' shows %times 6M, 1Y, 3Y, 5Y and 10Y rolling returns have been negative since inception of the fund.

Funds Managed by Chirag Dagli

Scheme Name	Managing Since	1 Year		3 Years		5 Years	
		Fund	Benchmark	Fund	Benchmark	Fund	Benchmark

DSP Healthcare Fund	Dec 01, 2020	10.47%	12%	21.55%	24.79%	14.71%	14.72%
DSP Multicap Fund	Jan 29, 2024	-0.76%	-0.61%	-	15.28%	-	14.19%

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement Different plans shall have a different expense structure. The performance details provided herein are of Regular Plan - Growth Option. **Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments.**

Disclaimer

SEBI Registration No: MF/036/97/7

The investment approach / framework/ strategy / portfolio / other data mentioned herein are dated and currently followed by the scheme and the same may change in future depending on market conditions and other factors.

The SIP returns are calculated by XIRR approach assuming investment of Rs. 10,000/- on the 1st working day of every month. XIRR helps in calculating return on investments given an initial and ?nal value and a series of cash in?ows and out?ows with the correct allowance for the time impact of the transactions. Load is not taken into consideration for computation of performance.

This email/note is for information purposes only. The recipient of this material should consult an investment/tax advisor before making an investment decision. In this material DSP Asset Managers Pvt. Ltd. (the AMC) has used information that is publicly available, including information developed in-house and is believed to be from reliable sources. The AMC nor any person connected does not warrant the completeness or accuracy of the information and disclaims all liabilities, losses and damages arising out of the use of this information. Data provided is as on**June 30, 2026** (unless otherwise specified and are subject to change without notice). **Past performance may or may not be sustained in the future and should not be used as a basis for comparison with other investments. There is no assurance of any returns/capital protection/capital guarantee to the investors in above mentioned scheme.**

For complete details on investment objective, investment strategy, asset allocation, scheme specific risk factors and more details, please read the Scheme Information Document, and Key Information Memorandum of the scheme available on ISC of AMC and also available on www.dspim.com.

*Expense ratio is subject to change in future depending on various factors

Portfolio details are as on **June 30, 2026**. Portfolio Allocation will be based on the prevailing market conditions and is subject to changes depending on the fund manager’s view of the equity markets.

Large-caps are defined as top 100 stocks on market capitalization, mid-caps as 101-250, small-caps as 251 and above.

All logos used in the image are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

The sector(s)/stock(s)/issuer(s) mentioned in this document do not constitute any recommendation of the same and the Fund may or may not have any future position in these sector(s)/stock(s)/issuer(s).

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Product Suitability	Scheme Riskometer	Benchmark^ Riskometer

This product is suitable for investors who are seeking*

- Long term capital growth
- Investment in equity and equity related Securities of healthcare and pharmaceutical companies





An open ended equity scheme investing in healthcare and pharmaceutical sector

*Investors should consult their financial advisors if in doubt about whether the scheme is suitable for them.

^ Benchmark : BSE HEALTHCARE (TRI)